Items related to biologics will be added to the top of the list as they are posted on the site.
07/01/2026 Expiration Date Extension for North American Coral Snake Antivenin (Micrurus fulvius) (Equine Origin) Lot CL6814 through December 31, 2026 07/01/2026 BK261345- HIV Combo Next Assay 07/01/2026 July 1, 2026 Approval Letter - TREGZI 06/30/2026 June 29, 2026 Approval Letter - AREXVY 06/29/2026 Important Information for Blood Establishments Regarding Ebola Disease and Blood Donation 06/29/2026 Recommendations for Assessment of Blood Donor Eligibility, Donor Deferral and Blood Product Management in Response to Ebola Virus; Guidance for Industry 06/29/2026 Cellular, Tissue, and Gene Therapies Advisory Committee Meeting Announcement Date: July 29, 202606/24/2026 BK261357- SeCore CDx HLA Sequencing System 06/24/2026 Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing; Draft Guidance for Industry Updated: June 24, 202606/23/2026 Master Protocols for Drug and Biological Product Development; Draft Guidance for Industry 06/23/2026 BK251252- MEDIFLY Maggots 06/23/2026 User Fee Billable Biologic Products and Potencies Approved Under Section 351 of the PHS Act 06/23/2026 Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products; Draft Guidance for Industry 06/22/2026 June 18, 2026 Approval Letter - THYMOGLOBULIN 06/22/2026 BK261349- cobas® HIV-1/HIV-2 Qualitative nucleic acid test for use on the cobas® 5800/6800/8800 systems 06/18/2026 CBER 2026 Orphan Approvals (new BLAs) 06/18/2026 June 16, 2026 Approval Letter - ZOLGENSMA 06/18/2026 June 17, 2026 Approval Letter - TECELRA 06/18/2026 June 17, 2026 Approval Letter - CAPVAXIVE 06/18/2026 June 17, 2026 Approval Letter - VAXNEUVANCE 06/17/2026 June 16, 2026 Approval Letter - ITVISMA 06/17/2026 June 15, 2026 Approval Letter - YESCARTA 06/17/2026 June 16, 2026 Approval Letter - TECARTUS 06/16/2026 June 15, 2026 Approval Letter - CASGEVY (125787) 06/15/2026 June 10, 2026 Approval Letter - PROCLEIX WNV ASSAY, Procleix Ultrio Elite Assay and Procleix Babesia Assay 06/15/2026 June 11, 2026 Approval Letter - HYQVIA 06/12/2026 June 12, 2026 Approval Letter - ODACTRA 06/10/2026 Public Webinar: FDA Review of Biologics License Applications for Blood and Source Plasma
Materials Added:
Recordings Transcript Slides Questions and Answers 06/10/2026 BK261333- Blood Product Questionnaire Module (v2.0.0) 06/05/2026 BK251274- RegenBMC® (RegenKit®-THT®-BMC) 06/05/2026 BK261335- LIAISON® MUREX HIV Ab/Ag HT; LIAISON®XL; LIAISON® diluteX 06/05/2026 BK261315- ELUclear Elution Kit 06/05/2026 June 4, 2026 Approval Letter - Elecsys Anti-HBc II 06/04/2026 SOPP 8406: CBER Processing of PDUFA Application Payments 06/04/2026 SOPP 8401.1: Issuance of and Review of Responses to Information Request Communications to Pending Applications 06/03/2026 Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities – Questions and Answers; Draft Guidance for Industry 06/02/2026 May 20, 2026 Safety Labeling Change Order and SLC Notification Letter - ADZYNMA 06/02/2026 Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorporating Genome Editing; Draft Guidance for Industry 05/29/2026 Frequently Asked Questions (FAQs): Electronic Submissions Program for CBER-Regulated Products 05/29/2026 COVID-19 Vaccines (2026-2027 Formula) for Use in the United States Beginning in Fall 2026 05/28/2026 BK261329- Erytra Eflexis
Content current as of:
07/01/2026